Company intelligence / Profile preview

Cara Therapeutics, Inc.

Stamford, Connecticut, United Statescaratherapeutics.com ↗

Ownership: Public · CARA
Development stage: Other

Overview

The company's lead product difelikefalin (KORSUVA) has shown mixed results in clinical trials. In June 2022, they announced positive topline results from the KOMFORT Phase 2 trial of oral difelikefalin for pruritus. However, in June 2024, they announced that oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo in the KOURAGE-1 Part A study for Notalgia Paresthetica, leading to discontinuation of that program.

Therapeutic areas: GastroenterologyNeurologyDermatologyNephrology
Modalities: PeptidesKappa opioid receptor agonists
Industry: Biotech

Partnerships

HealthCare Royalty ($40 million financing agreement)

Beyond the preview

Go deeper on Cara Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cara Therapeutics, Inc..